Hepatitis A is a beginning disease in childhood but sometimes a very dangerous disease in adults. It is necessary to vaccine the non immune "risk groups". Hepatitis B is responsible for two millions deafs every year. Hepatitis B is a sexually transmissible disease. Everybody would be vaccinated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Do children with type 1 diabetes mellitus remain protected against hepatitis B?
J Pediatr Endocrinol Metab
January 2025
Department of Medical Biochemistry, Health Science University, Prof Dr Cemil Taşcıoğlu City Hospital, Istanbul, Türkiye.
Objectives: Because patients with type 1 diabetes mellitus (T1DM) have persistent and profound limitations in immune functions, immune response to vaccines may diminish. The aim of our study was to compare the antibody to Hepatitis B surface antigen (anti-HBs) serologies of children with T1DM, at the time of T1DM diagnosis, who were vaccinated according to the vaccination schedule with the anti-HBs serologies of healthy children. And to investigate the relationship between anti-HBs levels and the accompanying variables of these patients.
View Article and Find Full Text PDFNationwide representative serosurvey of third-grade school children to evaluate the hepatitis B vaccination impact in Kyrgyzstan, 2022.
BMC Infect Dis
January 2025
WHO Regional Office for Europe, Marmorvej 51, Copenhagen, 2100, Denmark.
Background: Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts.
View Article and Find Full Text PDFHepatitis B infection (HBsAg and HBeAg) status among women attending antenatal care at public healthcare facilities of South Africa, 2017.
PLOS Glob Public Health
January 2025
Centre for Vaccines and Immunology, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.
Eight years after WHO adopted a resolution to eliminate hepatitis B by the year 2030, the disease remains a global public health concern, with vertical transmission of HBV being a major obstacle to this goal. Our study aimed to determine the HBV infection status of pregnant women in South Africa at a national level to evaluate the risk of vertical transmission and provide evidence for public health decision-making. We conducted HBsAg testing on 1,942 HIV-uninfected and 2,312 HIV-infected pregnant women from South Africa's public health sector in 2017, followed by HBeAg testing on HBsAg-positive samples.
View Article and Find Full Text PDFAnalysis of a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Beijing of China.
Hum Vaccin Immunother
December 2025
Center for Clinical Evaluation of Vaccines, Chaoyang District Center for Disease Control and Prevention, Beijing, China.
We report and analyze a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Chaoyang District of Beijing and to evaluate the causality between the disease and vaccination. Based on the professional branch of this case, we organized a seminar and we invited specialists in vaccinology, epidemiology, dermatology, infectiology, and immunology to participate in the conference. Specialists evaluated the relevance and causality between the vaccination and disease.
View Article and Find Full Text PDFLong-Term Immunity and Anamnestic Response Following Hepatitis B Vaccination: A Systematic Review and Meta-Analysis.
J Viral Hepat
February 2025
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Using a systematic review and meta-analytic approach, this study determined the durability of HBV immunity and the prevalence of anamnestic response to a booster HBV vaccine dose in individuals previously vaccinated with a 3-dose HBV vaccine series as children or adolescents. Two researchers independently searched PubMed, Embase and Cochrane from inception to 6/1/2023 and performed data extraction. Studies that included individuals with significant comorbidities or < 5 years of follow-up were excluded.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!